Predict your next investment

Corporation
HEALTHCARE | Pharmaceuticals / Drugs
jcrpharm.co.jp

See what CB Insights has to offer

Partners & Customers

9

About JCR Pharmaceuticals

JCR Pharmaceuticals is a producer of pharmaceutical products and medical injection devices. It also operates a medical reach and development lab for projects like biopharmaceuticals and stem cell therapy.

JCR Pharmaceuticals Headquarter Location

3-19 Kasuga-cho Ashiya

Hyogo, 659-0021,

Japan

+81 0797328591

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

JCR Pharmaceuticals Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

JCR Pharmaceuticals Rank

Latest JCR Pharmaceuticals News

JCR Pharmaceuticals : Financial Summary Consolidated Financial Results for the Year ended June 30, 2021 (FY2021) (Japanese Standard)

Sep 16, 2021

07/29 09/16/2021 | 01:32am EDT Message : JCR Pharmaceuticals Co., Ltd. (4552) Financial Summary (Japanese standard) Listed stock exchange: Tokyo Stock Exchange Code number: (Name) Shin Ashida (Title) Corporate Officer, Executive Director, Administration Division (Name) Yutaka Honda Scheduled date to commence dividend payments: - Preparation of supplemental information for this financial summary: None IR Conference: None 1. Consolidated Financial Results for 1Q FY2021 (April 1, 2021 to June 30, 2021) (1) Consolidated Operating Results (Cumulative) Net sales Three months ended June 30, 2020: 767 million yen (215.2%) Ernings per Share (Note) We conducted a 4-for-1 stock split on October 1, 2020. Calculations of "Earnings per share (basic)" and "Earnings per share (diluted)" are based on the assumption that the stock split was implemented at the beginning of the previous fiscal year. 31, 2021: 37,864 million yen 2. Dividends 2. We conducted a 4-for-1 stock split on October 1, 2020. The year-end dividend per share shown for the fiscal year ended March 31, 2021 reflects the impact of this stock split, and the annual dividend is presented as "-". If the stock split is assumed to have been implemented at the beginning of the previous fiscal year, the 2nd quarter-end dividend per share for the fiscal year ended March 31, 2021 would be 4.50 yen and the annual dividend per share would be 12.00 yen. 2. Breakdown of the year-end dividend for the fiscal year ended March 31, 2021 Ordinary dividend: 7.00 yen Commemorative dividend: 0.50 yen 3. Consolidated Forecasts for the Fiscal Year Ending March 31, 2022 (April 1, 2021 to March 31, 2022) (Percentage figures for the fiscal year represent the changes from the previous year.) Profit Translation - Original Text in Japanese JCR Pharmaceuticals Co., Ltd. (4552) *Note Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in consolidation scope): None Application of specific accounting practices for preparing quarterly consolidated financial statements: None Changes in accounting policy, changes in accounting estimates and restatements 1. Changes in accounting policy due to the revision of accounting standards, etc. :Yes 2. : None : None (Note) For details, please refer to "2. Quarterly consolidated financial statements and important notes, (3) Notes to quarterly consolidated financial statements, (Changes in accounting policy)" on page 9 of the attached material. Number of shares outstanding (common stocks) Number of outstanding shares Number of treasury stock as of the end of the period Average number of shares during the period (quarterly As of June 30, 2021 129,686,308 shares 129,686,308 shares 6,060,744 shares 6,071,644 shares 123,623,198 shares 123,324,858 shares cumulative amount) (Note) We conducted a 4-for-1 stock split on October 1, 2020. Calculations for "Average number of shares during the period" are based on the assumption that the stock split was implemented at the beginning of the previous fiscal year. The quarterly financial statements are outside of the scope of quarterly review by a certified public accountant or an audit firm. Explanation on the appropriate use of forecasts of financial results and other comments (Note on forward-looking statements, etc.) Forward-looking statements, such as forecasts of financial results, contained in this document are based on information currently available to the Company and certain assumption that are judged as rational. The Company does not assure the achievement of these forecasts. In addition, actual financial results may differ significantly from forecasts due to various reasons. For assumptions underlying forecasts of financial results and notes regarding the appropriate use of forecasts of financial results, please refer to "1. Qualitative information for quarterly financial statements, (3) Explanation on projections such as forecasts of consolidated financial results" on page 4 of the attached material. Translation - Original Text in Japanese JCR Pharmaceuticals Co., Ltd. (4552)  Table of Contents for Attached Material 1. JCR Pharmaceuticals Co., Ltd. (4552) 1. Qualitative information for quarterly financial statements Explanation on financial results Net sales amounted to 9,813 million yen (up 89.4% year on year). Sales of our mainstay products, such as our recombinant human growth hormone product GROWJECT®, increased year on year due to an increase in sales volume, despite an NHI price revision in April 2021. In addition, total net sales rose year on year as a result of sales launches for stock solution for AstraZeneca K.K. 's COVID-19 vaccine and IZCARGO® for I.V. infusion 10mg, which was added to the NHI price list in May 2021. Profits increased year on year at every level, with operating income of 2,984 million yen (up 280.3%), ordinary income of 3,000 million yen (up 247.6%), and quarterly profit attributable to owners of parent of 1,532 million yen (up 99.8%). In May 2021, we terminated an agreement concluded for first right of refusal pertaining to certain products currently in the preclinical stage of development upon mutual agreement of the parties. This resulted in a loss on contract termination of 1,000 million yen, which has been recorded as an extraordinary loss. As a result of proactive R&D activities, R&D expenses totaled 1,754 million yen (up 620 million yen, or 54.7%, year on year). Previous quarterly consolidated results JCR Pharmaceuticals Co., Ltd. (4552) Status of R&D [Treatments for lysosomal storage disorders] In treatments for lysosomal storage disorders, a priority field for development, we are currently conducting development of new drugs that employ our unique blood-brain barrier (BBB) technology, J-Brain Cargo® For pabinafusp alfa (development code: JR-141/ IZCARGO® for I.V. infusion 10mg), our BBB-penetrating product for the treatment of patients with Hunter syndrome, we commenced sales in Japan in May 2021. Furthermore, we filed for marketing approval of JR-141 in Brazil with the Brazilian Health Regulatory Agency (ANVISA) in December 2020. In other regions, JR-141 received orphan drug designation from the U.S. Food and Drug Administration (FDA) in October 2018 and the European Medicines Agency (EMA) in February 2019. Moreover, in February 2021, JR-141 received FDA Fast Track designation along with approval to begin a Phase III clinical trial. In addition to the U.S., we are preparing to start studies in Brazil and Europe as a global clinical trial. For our BBB-penetrating product candidate for the treatment of patients with mucopolysaccharidosis type I (MPS I) (development code: JR-171), we started a Phase I/II clinical trial in Japan and Brazil in October 2020 as our first global clinical trial, and received approval to begin clinical trials in the U.S. JR-171 received orphan drug designation from the U.S. Food and Drug Administration (FDA) in February 2021 and the European Medicines Agency (EMA) in March 2021 We have also been successively conducting R&D into other treatments for lysosomal storage disorders that employ J - Brain Cargo®, including a treatment for Pompe disease (development code: JR-162), a treatment for Sanfilippo syndrome type A (development code: JR-441), a treatment for Sly syndrome (development code: JR-443), and a treatment for Sanfilippo syndrome type B (development code: JR-446). We will also develop each of these treatments globally. [Regenerative medicine products] In July 2019, we commenced Phase I/II clinical trial of TEMCELL® HS Inj. for the additional indication of neonatal hypoxic ischemic encephalopathy (HIE) (development code: JR-031HIE). In February 2019, we commenced Phase I/II clinical trial of an allogeneic regenerative medical product using dental pulp stem cells (DPCs) for the indication of acute cerebral infarction with Teijin Limited. (development code: JTR- 161/JR-161). [Human growth hormone product] In July 2018, we started a Phase III clinical trial for an additional indication for GROWJECT® in patients with short stature homeobox-containing gene (SHOX) deficiency. In March 2021, we initiated a Phase II clinical trial of a recombinant long-acting growth hormone (development code: JR-142). 3 This is an excerpt of the original content. To continue reading it, access the original document here . Attachments

JCR Pharmaceuticals Acquisitions

1 Acquisition

JCR Pharmaceuticals acquired 1 company. Their latest acquisition was ArmaGen on March 27, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

3/27/2020

Series B

$27M

Acquired

2

Date

3/27/2020

Investment Stage

Series B

Companies

Valuation

Total Funding

$27M

Note

Acquired

Sources

2

JCR Pharmaceuticals Partners & Customers

9 Partners and customers

JCR Pharmaceuticals has 9 strategic partners and customers. JCR Pharmaceuticals recently partnered with AstraZeneca on August 8, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

8/7/2020

Client

AstraZeneca

United Kingdom

AstraZeneca taps JCR Pharmaceuticals, Daiichi Sankyo and other local pharmas to supply COVID-19 shots to Japan

AstraZeneca has tapped both Daiichi Sankyo proper and its Biotech label in the latest supply pact .

1

6/11/2019

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

10/24/2018

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

7/18/2017

Licensee

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

12/9/2016

Licensor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

8/7/2020

6/11/2019

10/24/2018

7/18/2017

12/9/2016

Type

Client

Licensor

Partner

Licensee

Licensor

Business Partner

AstraZeneca

Country

United Kingdom

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

News Snippet

AstraZeneca taps JCR Pharmaceuticals, Daiichi Sankyo and other local pharmas to supply COVID-19 shots to Japan

AstraZeneca has tapped both Daiichi Sankyo proper and its Biotech label in the latest supply pact .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

10

10

10

10

JCR Pharmaceuticals Team

1 Team Member

JCR Pharmaceuticals has 1 team member, including current Chief Executive Officer, Shin Ashida.

Name

Work History

Title

Status

Shin Ashida

Chief Executive Officer

Current

Name

Shin Ashida

Work History

Title

Chief Executive Officer

Status

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.